Okogen Acquires Ranpirnase Assets and Intellectual Property Portfolio @reportablenews
Plano, Texas--(Newsfile Corp. - March 26, 2026) - Okogen Inc., a biotechnology company developing antiviral therapeutics, today announced the acquisition of the global intellectual property portfolio and development assets for ranpirnase from Orgenesis Inc. (OTC: ORGS), strengthening the company's lead ophthalmic program and establishing a foundation for expansion into additional antiviral indications. The acquisition expands the company's development pipeline beyond ocular...
http://dlvr.it/TRjqRQ
http://dlvr.it/TRjqRQ
Comments
Post a Comment